RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Rubius Therapeutics Stock

Rubius Therapeutics Revenue 2024

Rubius Therapeutics Revenue

0 USD

Ticker

RUBY

ISIN

US78116T1034

WKN

A2JQ3H

In 2024, Rubius Therapeutics's sales reached 0 USD, a 0% difference from the 0 USD sales recorded in the previous year.

The Rubius Therapeutics Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2026e546.01-
2025e218.4-
2024e--
2023e--
2022--
2021--
2020--
2019--
2018--
2017--
2016--

Rubius Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Rubius Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Rubius Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Rubius Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Rubius Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Rubius Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Rubius Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Rubius Therapeutics’s growth potential.

Rubius Therapeutics Revenue, EBIT and net profit per share

DateRubius Therapeutics RevenueRubius Therapeutics EBITRubius Therapeutics Net Income
2026e546.01 M undefined-184.76 M undefined-108.69 M undefined
2025e218.4 M undefined-211.2 M undefined-86.45 M undefined
2024e0 undefined-75.48 M undefined-70.14 M undefined
2023e0 undefined-88.18 M undefined-59.99 M undefined
20220 undefined-127.25 M undefined-179.67 M undefined
20210 undefined-194.62 M undefined-196.55 M undefined
20200 undefined-166.45 M undefined-167.73 M undefined
20190 undefined-169.6 M undefined-163.46 M undefined
20180 undefined-91.66 M undefined-89.2 M undefined
20170 undefined-43.26 M undefined-44.5 M undefined
20160 undefined-10.85 M undefined-11.76 M undefined

Rubius Therapeutics stock margins

The Rubius Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Rubius Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Rubius Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Rubius Therapeutics's sales revenue. A higher gross margin percentage indicates that the Rubius Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Rubius Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Rubius Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Rubius Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Rubius Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Rubius Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Rubius Therapeutics Margin History

Rubius Therapeutics Gross marginRubius Therapeutics Profit marginRubius Therapeutics EBIT marginRubius Therapeutics Profit margin
2026e0 %-33.84 %-19.91 %
2025e0 %-96.7 %-39.58 %
2024e0 %0 %0 %
2023e0 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %

Rubius Therapeutics Aktienanalyse

What does Rubius Therapeutics do?

Rubius Therapeutics Inc is a US biotechnology company founded in 2013. The company's goal is to develop therapies based on artificially manufactured red blood cells, known as RBCs, to treat diseases for which effective treatment methods are currently unavailable. The idea for the creation of Rubius began with a discovery by Dr. Aviv Regev at the Broad Institute, a research institute in Cambridge, Massachusetts. She discovered a method for using artificially manufactured red blood cells to treat diseases. Rubius was launched to intensify research and development in this area and create groundbreaking therapies using a new technology. Rubius has a unique business model. The company relies on a novel development platform that focuses not on delivering drugs into cells, but on using red blood cells as a base. The technology enables the incorporation of special proteins or active ingredients into the RBCs' membrane. By selectively releasing these active ingredients into the bloodstream, diseases can be directly treated at their source. This approach offers many advantages, such as increased effectiveness and reduced side effects. Rubius is currently working on several product candidates in various clinical research programs. The company has three main areas of focus: immunology, rare diseases, and cancer. In the field of immunology, they are developing therapies for autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. The company also has a pipeline of products that can be used for rare blood disorders like hemophilia. Additionally, Rubius is involved in cancer immunotherapy, aiming to combat cancer cells by targeted activation of the immune system. Rubius Therapeutics has already achieved successes, such as the approval of an RBC-based drug for sickle cell disease by the US Food and Drug Administration (FDA) in spring 2020. The first target molecule on the RBC surface refers to the C5b9 membrane attack complex, which can cause damage to red blood cells, inflammation, and damage to blood vessels. Rubius aims to incorporate a specific protein into the artificial red blood cells that blocks the attack on red blood cells by the C5b9 membrane attack complex. As a leader in the biotechnology industry, Rubius is an innovative company with a novel business model and promising technology. It is shaping the industry with various developments and revolutionizing therapy for serious diseases that previously lacked satisfactory treatment methods. Overall, Rubius is a promising company with great potential for the future. Rubius Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Rubius Therapeutics's Sales Figures

The sales figures of Rubius Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Rubius Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Rubius Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Rubius Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Rubius Therapeutics stock

How much revenue did Rubius Therapeutics generate this year?

Rubius Therapeutics has achieved a revenue of 0 USD this year.

How much was the turnover of the company Rubius Therapeutics compared to the previous year?

The revenue of Rubius Therapeutics has increased by 0% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Rubius Therapeutics?

The revenue of Rubius Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Rubius Therapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Rubius Therapeutics so important for investors?

The revenue of Rubius Therapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Rubius Therapeutics pay?

Over the past 12 months, Rubius Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Rubius Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Rubius Therapeutics?

The current dividend yield of Rubius Therapeutics is .

When does Rubius Therapeutics pay dividends?

Rubius Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Rubius Therapeutics?

Rubius Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Rubius Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Rubius Therapeutics located?

Rubius Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Rubius Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Rubius Therapeutics from 12/29/2023 amounting to 0.058 USD, you needed to have the stock in your portfolio before the ex-date on 1/2/2024.

When did Rubius Therapeutics pay the last dividend?

The last dividend was paid out on 12/29/2023.

What was the dividend of Rubius Therapeutics in the year 2023?

In the year 2023, Rubius Therapeutics distributed 0 USD as dividends.

In which currency does Rubius Therapeutics pay out the dividend?

The dividends of Rubius Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Rubius Therapeutics

Our stock analysis for Rubius Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Rubius Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.